A granted Indian patent can be exploited in several ways: sell it outright, license it, manufacture the product yourself, or enforce it against infringers. Doing none of them is not free, because renewal fees alone run to between Rs 76,800 and Rs 384,000 over a full term. The right route depends on your capital, your risk appetite, and whether the patent is even granted yet.
This article covers the position under the Patents Act 1970 and the Patents Rules 2003 in India. It is a decision guide, not a how-to on any single route; fee figures are as verified in July 2026. The question is which route fits your situation, not how each is documented once you have chosen.
| The five decisions at a glance |
| • Sell: consideration as agreed, you exit, the buyer takes on the asset. • License: you keep ownership while another party works the invention for agreed consideration. • Manufacture: direct control of production, with the operational and market exposure that comes with it. • Enforce: you assert the exclusive right in court. A cost centre that sometimes converts, not a revenue route. • Maintain, surrender, or lapse: the patent still costs money and still carries obligations. Grant status gates your options. A pending application cannot be enforced, and a pre-grant transfer runs through Section 20, not the Section 69 recordal used after grant. Co-ownership gates them too: a co-owner cannot license or assign alone. |
Selling the patent outright
Selling ordinarily means assigning ownership of the patent for contractually agreed consideration. The assignee becomes the proprietor and takes over the renewal obligations. The payment structure, and any continuing obligations on either side, depend on the assignment agreement rather than on the Act.
An assignment must be in writing, embody all its terms and conditions, and be duly executed to be valid (Section 68). The assignee must then apply to the Controller to register its title, ordinarily on Form 16, and until that recordal the assignment document is generally not admissible as evidence of title or interest unless the Controller or a court directs otherwise (Section 69). How the assignment is drafted and recorded is covered in our guide to assignment agreements.
The trade-off is that you cannot un-sell: if the invention becomes a category leader, the buyer captures that value.
As a commercial default: sell when the patent sits outside the business you actually operate, and certainty is worth more to you than upside.
Licensing the patent
Licensing lets another party make, use, or sell the invention while you keep ownership. Consideration arrives on the payment structure agreed with the licensee, whether as royalties, fees, or a mix, and you can license the same patent to several parties or reserve it for one.
The appeal is that you monetise the patent without building a factory or a sales team. A licence must be in writing, embody all the terms and conditions governing the parties’ rights and obligations, and be duly executed (Section 68); the licensee must also apply to the Controller to register notice of its interest, ordinarily on Form 16 (Section 69). The choice between exclusive and non-exclusive, the royalty structures available, and the clauses that make a licence enforceable are the subject of our guide to how a patent licence works under Indian law. For the routing decision, three things matter.
First, where consideration is tied to sales, production, or use, your return depends on the licensee actually working the invention, so the counterparty’s capability is part of the decision; upfront fees and minimum payments turn on the structure you negotiate. Second, you remain a patentee, so the working-statement and renewal obligations stay with you. Third, restrictive terms can rebound: certain conditions are void under Section 140, and terms such as exclusive grant-back or coercive package licensing can be treated as a failure to satisfy the public’s reasonable requirements.
As a commercial default: license when you believe in the invention but cannot fund making it, and a capable counterparty exists.
Manufacturing and selling it yourself
Self-manufacture gives you direct control over production, pricing, and market execution: you produce the patented product and take it to market under your own brand. The net return depends on production costs, demand, competing rights, and execution, and you carry the operational and market exposure.
A patent is an exclusionary right, not a freedom-to-operate clearance. Section 48 gives you the right to stop others from making, using, or selling your invention. It does not, by itself, establish that manufacturing or selling your product avoids someone else’s patent. Before investing in tooling or a launch, a freedom-to-operate check is a separate exercise from owning the patent.
A middle path is to outsource production alone, selling under your own name. One trap sits inside this route. If the defendant in an infringement suit proves it was unaware, and had no reasonable grounds to believe, that the patent existed, the court cannot award damages or an account of profits (Section 111). Marking a product merely “patented” without the patent number is not enough to fix an infringer with notice.
As a commercial default: manufacture only when you can fund the launch and absorb a failed one.
Enforcing the patent against infringers
Enforcement is not a revenue route. It is a defensive spend that sometimes converts into one, and it is the most expensive option on this page. Where a third party makes, uses, or sells your invention without consent, you can sue. A court may grant an injunction and, at your option, either damages or an account of profits, and may order infringing goods destroyed (Section 108). The parties may separately negotiate a licence or settlement, but relief may be injunctive without any monetary recovery.
Two features shape the capital and risk profile. A suit must be brought in a district court or higher, and if the defendant counterclaims for revocation, the suit and counterclaim are transferred to the High Court (Section 104), changing the forum and the litigation profile. And enforcement is only available after grant. If you are weighing a suit, our guide to patent infringement in India sets out the reliefs and the process in full.
As a commercial default: treat enforcement as protecting a route you are already earning from, not as a route in itself.
Holding or exiting, and the cost of doing neither
Doing nothing looks free. It is not. A patent left idle runs a renewal schedule and carries compliance obligations.
Renewal fees are payable for the third year onward, counted from the date of the patent, ordinarily the filing date rather than the grant date (Sections 45 and 53, Rule 80). At the currently prescribed electronic-filing rates, the undiscounted renewal fees for years three to twenty total around Rs 76,800 for a natural person, startup, small entity, or educational institution, and around Rs 384,000 for other applicants (First Schedule, entry 18). These are official fees, not total maintenance cost, and a 10% reduction applies where at least four years are paid in advance electronically (Rule 80). Miss a renewal and the patent ceases to have effect, and the subject matter is not entitled to protection (Section 53). If restoration is later obtained, no suit may be commenced for infringement committed between the date of cessation and the date the restoration application was published (Section 62). Restoration may be sought within eighteen months of cessation on Form 15 (Section 60).
Every patentee and every licensee must separately file a working statement in Form 27, once for each three-financial-year period, the first starting with the financial year immediately after the year of grant, within six months of the period’s expiry (Section 146 and Rule 131). There is no official fee for Form 27, but failure to furnish it can attract a penalty of up to Rs 1 lakh, plus Rs 1,000 for each day the failure continues, adjudicated on a complaint in Form 32 which any person may file.
From three years after grant, any interested person may apply for a compulsory licence on grounds such as non-working in India, unaffordability, or unmet public demand (Section 84). Keep this in proportion: India has granted one compulsory licence under Section 84 in the provision’s history, to Natco against Bayer in 2012, and the applications since have been refused. All have been pharmaceutical. Treat it as a reason to document your working effort, not as a live threat to an ordinary engineering patent.
That is why holding is a decision, not a default. If it is not worth keeping, the deliberate exit is to offer it for surrender under Section 63: the offer is published, may be opposed by an interested person, and takes effect only if the Controller accepts it and revokes the patent. No official fee applies to the surrender notice.
As a commercial default: if you will not work, license, or sell the patent within the next renewal cycle, surrender it deliberately rather than letting it lapse by neglect.
Two checks before you choose
Do you own all of it? Where a patent is granted to two or more persons, each holds an equal undivided share unless agreed otherwise. Each co-owner may work the invention for their own benefit without accounting to the others, but a licence cannot be granted and a share cannot be assigned by one co-owner without the consent of the others (Section 50). So co-ownership leaves self-manufacture open while gating both the sale and the licensing routes. If a co-owner will not agree, the Controller has power to give directions on sale, lease or licensing (Section 51).
What leaves before the money reaches you? An assignment or licence is a transaction, and transactions carry cost the Patents Act does not govern: stamp duty on the instrument, which varies by state and by how the deal is structured; tax treatment of the consideration, which differs between a capital receipt on assignment and royalty income on a licence; withholding on royalties; and GST on licensing. None change which route is legally available; all change what you keep. Price them before you commit, particularly on a cross-border deal, where remittance and exchange-control rules also apply.
Comparing the five decisions
The routes differ on five axes founders actually weigh. The commercial columns are an illustrative profile, not a statutory consequence; the actual outcome turns on your agreement and your execution.
| Route | Upfront cost to you | Capital required | Risk you carry | Ownership | Money timing |
| Sell | Transaction, diligence, documentation, recordal, stamp duty | Usually limited after completion; agreement-dependent | Largely shifts to buyer; residual per the agreement | Transferred | As agreed in the assignment |
| License | Negotiation and drafting | Generally lower than manufacture; deal-dependent | Allocated by the licence terms | Retained | As agreed in the licence |
| Manufacture | Production and market build | High | High | Retained | After market entry |
| Enforce | Litigation cost | Medium to high | High; case can escalate | Retained | Uncertain; may be injunctive, not monetary |
| Maintain or exit | Renewal and compliance; no official fee for surrender notice | Renewal and compliance spend | Compliance, and remote compulsory-licence exposure | Retained until surrender, cessation, or expiry | None |
Matching the route to your situation
| Your situation | Usual starting point | Why |
| Research-led, no manufacturing base | License, or sell | Avoids the capital call; selling gives the cleaner exit |
| Cash-constrained, but you believe in the invention | Non-exclusive licensing | Consideration from more than one licensee without funding a build |
| Product is market-ready and you can fund it | Manufacture | Most direct control of returns, at the greatest operational commitment |
| Someone is already infringing | Assess first, then enforce or negotiate | Enforcement is a cost centre; a negotiated licence often remains available |
| Co-owned patent, co-owner not aligned | Self-manufacture, or resolve consent | Section 50 blocks licensing and assignment, not working |
| No counterparty and no route to market | Reassess whether to maintain | The binding constraint is demand for the asset, not the law |
A note from practice. In our experience the constraint that decides this is rarely the statute. Most Indian patentees weighing a sale or a licence have not yet identified anyone who wants the asset, and the honest first step is to test that before optimising between routes. Valuation and drafting matter, but neither creates a buyer.
Two inputs sharpen these choices. The first is what the patent is worth, which informs the assignment consideration or licence terms; our guide to patent valuation methods in India covers how that number is built. The second is your renewal horizon: if you will not work, license, or sell the patent, the honest question is whether to keep paying to renew it at all.
If your patent has not been granted yet
A pending application is a different decision. Infringement proceedings are not available until grant, and a pre-grant transfer runs through a different mechanism than the Section 69 recordal applying after grant.
From publication until grant, you have the like privileges and rights of a patentee, but you cannot institute infringement proceedings until the patent is granted (Section 11A). Pending status does not, however, stop you from commercially exploiting the invention or from assigning the application. A person who becomes entitled to the application through a written assignment or agreement may seek substitution as the applicant under Section 20, on Form 6. A pre-grant licensing arrangement is contractual and does not itself substitute the applicant. Only enforcement waits for grant, and any activity you document meanwhile is potentially infringing activity, to be assessed against the claims finally granted.
One pressure is absent. The three-year compulsory-licence period runs from the date of grant, not from filing, so a pending application carries no compulsory-licence exposure and no Form 27 obligation yet. The practical move while pending is to prepare and, where it fits, to transact: settle whether you will sell, license, or manufacture, and value the invention, so you can act at grant.
Deciding your first move
Start with three facts about your patent: is it granted, do you own all of it, and can you fund working it yourself. Granted, wholly owned and funded opens every route. Granted but unfunded points to licensing or sale. Co-owned without consent closes licensing and assignment but leaves manufacture open. Pending status permits assignment of the application under Section 20, while enforcement waits for grant.
Whichever way you lean, the route you can defend commercially is the one built on a real valuation, a named counterparty, and a clear read of your own capacity to carry risk.
Frequently asked questions
Common routes for a granted patent are selling it by assignment, licensing it for consideration, manufacturing and selling it yourself, or enforcing it against infringers under the Patents Act 1970. Alongside these sits the decision to maintain, surrender, or let the patent lapse. The right route depends on capital, ownership, and grant status.
Yes. Selling assigns ownership to a buyer for agreed consideration, and you exit the asset; the assignee registers its title under Section 69. Licensing keeps ownership with you while another party works the invention. Both an assignment and a licence must be in writing and duly executed under Section 68.
The patent still needs renewal fees, which total around Rs 76,800 to Rs 384,000 across the full term, and still carries a Form 27 working-statement obligation. Failing to file Form 27 can attract a penalty. Offering the patent for surrender under Section 63 carries no official fee and is cleaner than an accidental lapse.
Not alone. Under Section 50 a co-owner cannot grant a licence or assign a share without the consent of the other co-owners, unless an agreement says otherwise. Each co-owner may, however, work the invention for their own benefit. The Controller can give directions where co-owners disagree (Section 51).
You cannot enforce it: infringement proceedings cannot be instituted until the patent is granted (Section 11A). You can, however, exploit or assign the application; a person entitled through a written assignment may seek substitution as applicant under Section 20 on Form 6. Only enforcement waits for grant.
Disclaimer: This article is general information on patent commercialisation under Indian law and is not legal advice. It does not address tax or stamp duty, which vary by state and by transaction structure and require separate advice. Fee figures and statutory positions are stated as verified in July 2026 and are subject to change. Obtain advice from a qualified patent professional before acting.